Published in Exp Ther Med on May 12, 2011
Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer (2013) 1.00
Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer. Sci Rep (2015) 0.84
Value of serum marker HE4 in pulmonary carcinoma diagnosis. Int J Clin Exp Med (2015) 0.81
Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer. Dis Markers (2016) 0.81
Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. Acta Pharmacol Sin (2014) 0.80
EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer Biol Ther (2016) 0.79
Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Medicine (Baltimore) (2015) 0.77
History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer. Surg Today (2017) 0.76
Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Med (2015) 0.76
Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis. Oncotarget (2017) 0.75
Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study. J Thorac Dis (2016) 0.75
Retraction: Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J 2012;53:931-9. Yonsei Med J (2013) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med (1965) 12.88
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol (1999) 4.65
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell (1989) 3.81
Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res (2000) 1.81
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer (2001) 1.66
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52
Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med (2004) 1.20
Tumor-associated (CEA-reacting) antigen in patients with inflammatory bowel disease. N Engl J Med (1972) 1.18
Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol (2008) 1.17
Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg (2007) 1.17
Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg (2004) 1.17
Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer (2007) 1.03
Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer (2008) 1.03
Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem (1993) 0.99
Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol (1997) 0.96
Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Respiration (1995) 0.95
Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer (2005) 0.95
Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer (2007) 0.90
CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer (2005) 0.89
Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg (2004) 0.87
Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers. Anticancer Res (2000) 0.81
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med (2012) 6.73
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol (2007) 3.70
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res (2010) 2.48
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut (2012) 2.36
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med (2011) 2.19
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol (2005) 1.95
Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer (2007) 1.85
Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer. Ann Thorac Surg (2011) 1.80
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat (2007) 1.68
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2008) 1.67
Pulmonary inflammatory pseudotumor--a report of 28 cases. Korean J Intern Med (2002) 1.66
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.63
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med (2013) 1.62
CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med (2011) 1.59
Clinical outcomes and prognosis of recurrent thymoma management. J Thorac Oncol (2012) 1.54
The role of surgical treatment in second primary lung cancer. Ann Thorac Surg (2011) 1.53
Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc Natl Acad Sci U S A (2012) 1.53
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol (2007) 1.53
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer (2007) 1.49
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer (2011) 1.49
Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Respir Med (2012) 1.48
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
T-stage of non-small cell lung cancer directly invading an adjacent lobe. Eur J Cardiothorac Surg (2012) 1.46
Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg (2008) 1.46
The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci (2006) 1.44
[Analysis of survival and factors affecting the survival after surgical resection of peripheral cholangiocarcinoma: 318 cases in single institute]. Korean J Hepatol (2007) 1.42
Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol (2008) 1.42
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Support Care Cancer (2013) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer (2003) 1.41
Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun (2004) 1.41
A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. Hum Mol Genet (2003) 1.40
High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res (2012) 1.39
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
Transcervical intraluminal repair of posterior membranous tracheal laceration through semi-lateral transverse tracheotomy. J Thorac Cardiovasc Surg (2007) 1.37
Questionable role of interferon-γ assays for smear-negative pulmonary TB in immunocompromised patients. J Infect (2011) 1.33
Delta neutrophil index as an early marker of disease severity in critically ill patients with sepsis. BMC Infect Dis (2011) 1.30
Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest Endosc (2003) 1.29
Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. Scand J Infect Dis (2012) 1.28
Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer (2007) 1.26
Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis (2008) 1.26
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat (2009) 1.25
Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol (2007) 1.24
Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol (2006) 1.23
Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res (2008) 1.21
Retracted Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J (2012) 1.20
Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. Ann Thorac Surg (2004) 1.20
Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis (2010) 1.17
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology (2011) 1.17
The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. J Surg Oncol (2009) 1.17
Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J (2012) 1.16